KR101870210B1 - Anti-aging composition comprising aster plant extracts - Google Patents

Abstract

In this specification, an anti-aging composition comprising an extract of Aster L. plant, a fraction thereof, or a compound isolated therefrom as an active ingredient is disclosed. The anti-aging composition has an effect of preventing, delaying or improving the skin change caused by aging. In addition, the anti-aging composition inhibits the expression or activity of collagenase or promotes the expression or activity of collagen, thereby preventing or improving wrinkles of the skin and improving skin elasticity.

Description

Anti-aging composition containing an extract of the genus Antimiata as an active ingredient {ANTI-AGING COMPOSITION COMPRISING ASTER PLANT EXTRACTS}

The present specification discloses an anti-aging composition comprising an extract of a plant of the genus Anthemis as an active ingredient.

The skin protects the internal organs from stimuli from the external environment, and plays an important role in maintaining biological homeostasis such as body temperature control. Such skin aging occurs due to various internal/external factors, and is largely divided into endogenous aging due to genetic causes and exogenous aging due to environmental causes. Among them, photoaging means aging due to ultraviolet (UV) rays. Recently, the destruction of the ozone layer due to environmental pollution increased the amount of ultraviolet rays, and accordingly, research on photoaging is drawing attention (Wang SQ et al., Dermatol. Ther. 23(1):31-47, 2010). In photoaging skin, appearance features such as roughness, loss of elasticity, occurrence of wrinkles, or irregular pigmentation are observed. Among them, the main research field of photoaging is on changes in skin wrinkles. In relation to the formation of wrinkles in the skin due to photoaging, a number of research results have been reported on basic physiological metabolic changes such as the synthesis, decomposition and moisture content of collagen, which is a major component of the skin (Brenneisen et al., Ann. NY Acad. Sci., 973:31-43, 2002).

Collagen present in the dermal layer of the skin accounts for about 70 to 80% of the total dry weight of the skin, and is known to control skin elasticity along with elastin, an elastic fiber. In particular, the generation of reactive oxygen species is increased by ultraviolet rays and the breakdown of the enzymatic/non-enzymatic antioxidant defense system of the skin is caused, thereby increasing the degradation of collagen and reducing biosynthesis, resulting in a remarkable decrease in collagen in the dermal layer. (Bickers DR, Athar M, J. Invest. Dermatol., 126(12):2565-2575, 2006). An important influence on the reduction of collagen is collagen-degrading enzymes (MMPs), which are involved in the decomposition of the extracellular matrix and the basement membrane. Research results have been reported that the activity of the enzyme is increased by ultraviolet light and that by inhibiting it, the increase in skin thickness and wrinkle formation induced by ultraviolet light is reduced (Inomata S et al., J. Invest. Dermatol., 120((Inomata S et al., J. Invest. 1):128-134, 2003). Therefore, for the prevention and treatment of photoaging, controlling MMPs is an effective method.

Meanwhile, hyaluronic acid, a constituent of the dermal layer of the skin, is a component that fills the collagens in the dermal layer to maintain moisture and elasticity of the skin. In particular, ultraviolet rays reduce the amount of hyaluronic acid, thereby reducing the moisture content in the skin and increasing the amount of transdermal moisture loss, causing damage to the skin barrier. As a result, the skin becomes rough and the elasticity decreases, resulting in wrinkles (Baumann L, J. Pathol., 211(2):241-251, 2007). In other words, loss of moisturizing power of the skin is a major cause of skin aging.

The expectations and interests of consumers around the world for wrinkle improvement, starting with retinol, have been diversifying their types and functions such as natural extracts, adenosine, and cell growth factors since the 2000s (Lee EJ et al., Journal of the) Korean Society of Cosmetology, 17(1):127-133, 2011). The existing method was to prepare and use cosmetics or pharmaceuticals containing retinoids, ascorbic acid, tocopherol and hyaluronic acid.

However, active ingredients for improving skin wrinkles or skin aging that are currently being developed cannot be used as raw materials for some cosmetics, or they are very unstable and difficult to deliver to the skin, requiring a special stabilization system and delivery system, and improving skin wrinkles. There is a problem that the effect is not visible. For example, retinoids, which are effective ingredients for skin wrinkle improvement, are used to improve photoaging phenomena such as wrinkle formation and elasticity reduction by inhibiting collagen degradation enzymes and increasing collagen synthesis. It causes side effects such as skin irritation and has a problem that it is effective for long-term use (Rabe JH, J. Am. Acad. Dermatol., 55:1-19, 2006).

Korean Patent Application Publication No. 1999-0038402

In one aspect, the present specification aims to provide an anti-aging composition comprising an extract of a plant of Aster L., a fraction thereof, or a compound isolated therefrom as an active ingredient.

In one aspect, the technology disclosed in the present specification provides an anti-aging composition comprising an extract of a plant of Aster L. as an active ingredient.

In an exemplary embodiment, the plant of the genus ants is selected from the group consisting of ant odor (Aster tataricus L. f.), ant ant odor (Aster tripolium L.), ant ant odor (Aster maakii REGEL) and bee ant odor (Aster koraiensis NaKai). It can be 1 or more.

In an exemplary embodiment, the plant of the genus ants may be a bee ants (Aster koraiensis NaKai).

In an exemplary embodiment, the extract of the genus antacid plant may be extracted with one or more solvents selected from the group consisting of water and an alcohol having 1 to 6 carbon atoms.

In an exemplary embodiment, the extract of the plant of the genus Anthemis may be an ethanol extract.

In an exemplary embodiment, the extract of the genus antacid plant may be included in an amount of 0.001 to 80% by weight based on the total weight of the composition.

In another aspect, the technology disclosed in the present specification provides a composition for anti-aging comprising a compound represented by the following Formula 1, a derivative thereof, a salt thereof, a hydrate thereof, a solvate thereof, a prodrug thereof, or an isomer thereof as an active ingredient.

[Formula 1]

는 단일 또는 이중결합이다.In the above formula, R ₁ and R ₂ are each selected from the group consisting of hydrogen, oxygen, hydroxy, C ₁ to C ₄ alkyl ester and C ₁ to C ₄ alkoxy, and any of R ₁ and R ₂ When one is oxygen and the other is hydrogen, R ₁ or R ₂ is an epoxide bonded to two adjacent carbons thereto,

Is a single or double bond.

In an exemplary embodiment, the compound may be a compound represented by Formula 2 below.

[Formula 2]

In an exemplary embodiment, the compound may be isolated from an extract of a plant of Aster L. or a fraction thereof.

In an exemplary embodiment, the compound may be included in an amount of 0.0001 to 10% by weight based on the total weight of the composition.

In one exemplary embodiment, the composition may be for anti-aging against photoaging.

In an exemplary embodiment, the composition may be for improving skin wrinkles.

In an exemplary embodiment, the composition may be for enhancing skin elasticity.

In one aspect, the technology disclosed in the present specification has the effect of providing an anti-aging composition comprising an extract of a plant of Aster L., a fraction thereof, or a compound isolated therefrom as an active ingredient.

The anti-aging composition has an effect of preventing, delaying or improving skin changes due to aging.

The anti-aging composition has an effect of preventing or improving skin wrinkles and enhancing skin elasticity by inhibiting the expression or activity of collagen-degrading enzyme, or by promoting the expression or activity of collagen.

The anti-aging composition contains an extract of a natural product-derived Aster L. plant, a fraction thereof, or a compound isolated from these as an active ingredient, so that the possibility of occurrence of side effects is remarkably low and the use stability is high.

1 shows the effect of inhibiting the secretion of collagen-degrading enzyme-1 by each of the bee ant odor extract and the compound of Formula 2 according to an embodiment of the present specification. (*p<0.05, **p<0.01)
Figure 2 shows the effect of increasing the secretion amount of type-1 procollagen by each of the bee ant odor extract and the compound of Formula 2 according to an embodiment of the present specification. (*p<0.05, **p<0.01)
3 shows the effect of reducing the expression level of collagenase by each of the extract of bee gill odor and the compound of Formula 2 according to an embodiment of the present specification.
4 is a view showing the effect of increasing the expression amount of collagen by each of the bee ant odor extract and the compound of Formula 2 according to an embodiment of the present specification.

Hereinafter, the present invention will be described in detail.

In one aspect, the present specification provides an anti-aging composition comprising an extract of a plant of Aster L. as an active ingredient.

In the present specification, the "active ingredient" refers to an ingredient that can exhibit a desired activity by itself, or that can exhibit a desired activity together with a carrier that is not active by itself.

Aster L. plant is a dicotyledonous plant, a perennial plant of the Asteraceae family, and lives in wetlands in Korea, Japan, northern and northeastern China, Mongolia, and Siberia.

In an exemplary embodiment, the plant of the genus ants is selected from the group consisting of ant odor (Aster tataricus L. f.), ant ant odor (Aster tripolium L.), ant ant odor (Aster maakii REGEL) and bee ant odor (Aster koraiensis NaKai). It can be 1 or more. The bee ant michwi is also called separate ant michwi and Goryeo wormwood.

The anthill plant can be used without limitation over the entire range of plants including some or all of the above-ground or underground portions for the production of extracts, for example, one or more selected from the group consisting of leaves, stems, and roots. Can be used. In addition, the plant of the genus ants can be used throughout all periods of the growth stage, for example, young shoots can be used. In addition, the plants of the genus ants can be used without restrictions such as cultivated or commercially available.

In an exemplary embodiment, the extract of the plant of the genus ants is meant to include not only a crude extract, but also a processed product of the extract, for example, drying, concentration, fractionation, fermentation, etc. through additional processing.

In an exemplary embodiment, the extract of the plant of the genus Forte may be the plant itself, or an extract obtained through an extraction process or powdering the plant. The extraction process may be carried out according to a conventional method used in the art.

In an exemplary embodiment, the extract of the forsythia plant is water, an anhydrous or hydrous alcohol having 1 to 6 carbon atoms (eg, methanol, ethanol, propanol or butanol), propylene glycol, butylene glycol, dipropylene glycol, glycerin, Extraction solvent selected from the group containing acetone, ethyl acetate, chloroform, methylene chloride, butyl acetate, diethyl ether, dichloromethane, hexane, cyclohexane, ether, petroleum ether, benzene, and mixtures thereof, specifically water, methanol And it may be an extract extracted with one or more extraction solvents selected from the group containing ethanol. The extraction solvent is not limited to the extraction solvents listed above, and the specific amount of the extraction solvent is 5 to 100 times the weight of each sample to be extracted.

In an exemplary embodiment, the extract of the ant odor plant is supercritical extraction, subcritical extraction, high temperature extraction, high pressure extraction, ultrasonic extraction, fermentation or natural fermentation metabolism using microorganisms, or adsorption resin containing XAD and HP-20 It can be prepared according to a conventional extraction method in the art, such as a method using. Specifically, it may be heated and extracted at reflux or at room temperature, but is not limited thereto. In addition, the number of extractions may be 1 to 5 times, but specifically, extraction may be repeated 3 times, but is not limited thereto. The extraction time may be 2 to 24 hours, specifically 2 to 12 hours, or 3 to 10 hours, or 3 to 5 hours, but is not limited thereto.

In an exemplary embodiment, the extract of the genus antacid plant may be included in an amount of 0.001 to 80% by weight based on the total weight of the composition. Since the extract of the plant of the genus Anthemis is included in the above range in the composition, it has an effect of showing excellent anti-aging efficacy with an appropriate composition ratio with other containing materials, and may be preferable in terms of economy and efficiency. Specifically, the extract of the plant of the genus Anthemis is 0.005 to 78% by weight, or 0.01 to 76% by weight, or 0.05 to 74% by weight, or 0.1 to 72% by weight, or 0.5 to 70% by weight, based on the total weight of the composition, or 1.0 to 68% by weight, or 1.0 to 66% by weight, or 1.0 to 64% by weight, or 1.0 to 62% by weight, or 1.0 to 60% by weight, or 1.0 to 50% by weight, or 1.0 to 40% by weight, or 1.0 It may be included in to 30% by weight, or 1.0 to 20% by weight, or 1.0 to 10% by weight.

In another aspect, the present specification provides a composition for anti-aging comprising a compound represented by the following Formula 1, a derivative thereof, a salt thereof, a hydrate thereof, a solvate thereof, a prodrug thereof, or an isomer thereof as an active ingredient.

[Formula 1]

는 단일 또는 이중결합이다.In the above formula, R ₁ and R ₂ are each selected from the group consisting of hydrogen, oxygen, hydroxy, C ₁ to C ₄ alkyl ester and C ₁ to C ₄ alkoxy, and any of R ₁ and R ₂ When one is oxygen and the other is hydrogen, R ₁ or R ₂ is an epoxide bonded to two adjacent carbons thereto,

Is a single or double bond.

In an exemplary embodiment, the compound of Formula 1 may be a compound represented by the following Formulas 2 to 5.

[Formula 2]

[Formula 3]

[Formula 4]

[Formula 5]

In the present specification, "derivative" refers to all compounds that are changed with other substituents at the positions of the compounds capable of being substituted. _{There is no limitation on the kind of these substituents, such as C 1-10} which may each independently be substituted with hydroxyl, phenoxy, thienyl, furyl, pyridyl, cyclohexyl, alkyl alcohol, alkyldialcohol or optionally substituted phenyl. Bicyclic hydrocarbon group; _{C 5-6} cyclic hydrocarbon group which may be substituted with hydroxyl, hydroxymethyl, methyl or amino; Or it may contain a sugar moiety. In the present specification, the term "sugar moiety" refers to a group when one hydrogen atom is removed from a polysaccharide molecule, and thus may mean, for example, a moiety derived from a monosaccharide or an oligosaccharide.

_{Specifically, in the present specification, the "compound derivative" refers to a C 1} to C ₁₈ alkyl group, C ₁ to which a substituent including only hydrogen or an alkyl group in Formula 1 is unbranched or branched. C ₁₈ alkoxy group, C ₁ to C ₁₈ alkenyl group, C ₁ to C ₁₈ alkynyl group or C ₃ to C ₆ cyclic alkyl group All compounds obtained by substituting with may be included.

In the present specification, "salt" or "pharmaceutically acceptable salt" refers to a salt according to one aspect of the present specification, which is pharmaceutically acceptable and has a desirable pharmacological activity of a parent compound. And conventional salts formed with inorganic or organic acids or inorganic or organic bases, and acid addition salts of quaternary ammonium. The salt is (1) formed of an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or the like; Or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-Toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo [2,2,2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert -Acid addition salts formed from organic acids such as butyl acetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid; Or (2) a salt formed when an acidic proton present in the parent compound is substituted. More specific examples of suitable base salts are sodium, lithium, potassium, magnesium, aluminum, calcium, zinc, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucosamine and pro Contains salts of Caine.

As used herein, "pharmaceutically acceptable" means that it can be used in animals, more specifically in humans, by avoiding significant toxic effects when used in a conventional medicinal dosage. It means available or approved, listed in the pharmacopoeia, or recognized as other general pharmacopoeia.

In the present specification, "hydrate" refers to a compound to which water is bound, and is a broad concept including an inclusion compound having no chemical bonding force between water and the compound.

In the present specification, "solvate" refers to a high-order compound formed between molecules or ions of a solute and molecules or ions of a solvent.

In the present specification, "prodrug" refers to a drug in which physical and chemical properties are controlled by chemically changing a drug. It can exert its medicinal effect by changing to a drug of When administered, prodrugs are converted into active drugs through chemical transformation through metabolic processes. In general, these prodrugs are functional derivatives of the compounds according to the present specification, and are easily converted into the desired compounds in vivo. For example, conventional methods for selecting and preparing suitable prodrug derivatives are described in "Design Of Prodrugs", H Bund Saard, Elsevier, 1985. The entire contents of this document are incorporated herein by reference.

"Isomer" refers to a relationship between compounds having the same formula but not the same, and types of such isomers include structural isomers, geometric isomers, optical isomers and stereoisomers. Structural isomers refer to compounds having the same molecular formula but different structures and different properties, and geometric isomers refer to isomers having different spatial arrangements of atoms or groups bonded to two atoms connected by double bonds, and stereoisomers refer to the same It refers to compounds having a chemical composition but different in terms of the arrangement of atoms or groups in space, and optical isomers (enantiomers) refer to two stereoisomers of a compound having non-overlapping mirror images, and diastereomers refer to two or more It refers to a stereoisomer that has an asymmetric center and its molecules are not mirror images of each other.

As used herein, "isomers" refer to optical isomers (eg, essentially pure enantiomers, essentially pure diastereomers, or mixtures thereof), as well as conformational isomers. isomers) (i.e., isomers that differ only in the angle of one or more chemical bonds), position isomers (e.g. tautomers) or geometric isomers (e.g., cis-trans isomers). .

In the present specification, "essentially pure" means, for example, when used in connection with enantiomers or diaisomers, specific compounds exemplified by enantiomers or diaisomers are at least about 90%, preferably at least about 95%. , More preferably at least about 97% or at least about 98%, even more preferably at least about 99%, and even more preferably at least about 99.5% (w/w).

In an exemplary embodiment, the compound of Formula 1 may be commercially available, or may be obtained from natural products including plants of the genus ants, or synthesized by an organic chemical synthesis method.

In an exemplary embodiment, the compound of Formula 1 may be isolated from an extract of a plant of Aster L. or a fraction thereof.

For example, the compound of Formula 1 may be obtained by adding an extraction solvent consisting of water, an organic solvent, or a mixture thereof to a plant of the genus Forte (Step 1); Fractionating the extract obtained in step 1 to obtain a fraction (step 2); And separating and purifying the compound of Formula 1 by performing silica gel chromatography on the fraction obtained in step 2 (step 3).

The fraction in step 2 may be an n-hexane fraction obtained by systematic fractionation sequentially using n-hexane, ethyl acetate, n-butanol, and water, an ethyl acetate fraction, an n-butanol fraction, and a water fraction.

In addition, the fraction in step 2 may be a fraction obtained using at least one effluent solvent selected from the group consisting of hexane, ethyl acetate, and methanol.

In step 3, silica gel chromatography may be performed using a column for size exclusion chromatography, and preferably a column filled with Sephadex LH-20 may be used. The fraction obtained in step 2 may be subjected to silica gel chromatography using a Sephadex LH-20 column using 100% methanol as a mobile phase. At this time, the compound of Formula 1 may be separated by performing high performance liquid chromatography on the obtained fraction.

The high performance liquid chromatography may be performed using a mixed solvent of water and acetonitrile in a concentration gradient from 20% by volume to 30% by volume, from 25% by volume to 40% by volume, and from 25% by volume acetonitrile as a developing solvent. At this time, the flow rate of the mobile phase is preferably 2 to 15 ml/min, and the execution time is preferably 0.5 to 1 hour.

In an exemplary embodiment, the compound of Formula 1 may be included in an amount of 0.0001 to 10% by weight based on the total weight of the composition. When the compound of Formula 1 is included in the above range in the composition, it has an appropriate composition ratio with other substances and exhibits excellent anti-aging efficacy, and may be preferable in terms of economy and efficiency. Specifically, the compound of Formula 1 is 0.0005 to 10% by weight, or 0.001 to 10% by weight, or 0.005 to 10% by weight, or 0.01 to 10% by weight, or 0.01 to 8% by weight, or 0.01 based on the total weight of the composition. It may be included in to 6% by weight, or 0.01 to 4% by weight.

In the present specification, "anti-aging" refers to a use of preventing, delaying, or improving aging caused by internal factors including genetic factors and external factors including ultraviolet rays. For example, it means preventing, delaying, improving, or alleviating phenomena of skin changes caused by aging, such as reduction of skin elasticity, wrinkle formation, increase in the depth or number of wrinkles, and dryness.

In an exemplary embodiment, the composition may be a composition for anti-aging against photoaging.

In an exemplary embodiment, the composition may be an anti-aging composition that improves skin wrinkles or improves skin elasticity. Specifically, the composition has an effect of preventing or preventing wrinkle formation by delaying the generation time of wrinkles as much as possible, or alleviating or improving wrinkles that have already been created. In addition, the composition has an effect of preventing or preventing a decrease in skin elasticity, or promoting or improving skin elasticity.

The composition may inhibit the expression of collagenase or may inhibit the activity of a collagenase that is slightly expressed by the composition of the present specification. In another aspect, the composition may have a specific effect on substances such as up-stream enzymes or proteins that inhibit the expression or activity of collagenase.

The composition may promote the expression of collagen or enhance its activity. In another aspect, the composition may have a specific effect on substances such as up-stream enzymes or proteins that increase the expression or activity of collagen.

In an exemplary embodiment, the anti-aging composition may be a pharmaceutical composition.

In the present specification, the pharmaceutical composition may include a composition for external application for skin. The formulation of the pharmaceutical composition may be a solution, a suspension, an emulsion, a gel, a drop, a suppository, a cream, an ointment, a patch, a pad, or a spray, but is not limited thereto. The formulation can be easily prepared according to conventional methods in the art, and excipients, hydrating agents, emulsification accelerators, suspending agents, salts or buffers for controlling the osmotic pressure, coloring agents, spices, stabilizers, preservatives, preservatives or other compatible Adjuvants can be used in moderation.

In addition, the pharmaceutical composition may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous, etc. according to a desired method, and the active ingredient of the pharmaceutical composition is the age of the subject to be administered, It will depend on sex, weight, pathologic condition and severity, route of administration, or the judgment of the prescriber. Determination of the application amount based on these factors is within the level of those skilled in the art, and its daily dose is, for example, 0.1 mg/g/day to 100 mg/g/day, more specifically 5 mg/g/day to 50 mg/day. It may be g/day, but is not limited thereto.

In an exemplary embodiment, the anti-aging composition may be a cosmetic composition.

In the present specification, the formulation of the cosmetic composition is not particularly limited, and may be appropriately selected depending on the intended purpose. For example, it may be prepared in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a foam, or an aerosol composition. It is not limited.

In addition, the cosmetic composition may further include other ingredients capable of giving a synergistic effect to the main effect within a range that does not impair the main effect in addition to the above-described substances. In addition, the cosmetic composition is a fatty substance, an organic solvent, a solubilizing agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or nonionic emulsifier. , Fillers, sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other ingredients commonly used in cosmetics, such as cosmetic or It may contain adjuvants commonly used in the field of dermatology. The blending amount of the ingredients can be easily selected and used by a person skilled in the art within a range that does not impair the purpose and effect of the present specification, and the blending amount is 0.01 to 5% by weight, or 0.01 to 3% by weight based on the total weight of the composition. I can.

In one exemplary embodiment, the composition may be a food composition.

In the present specification, the food composition provides various types of food additives or functional foods. Specifically, it may be processed into leached tea, liquid tea, beverages, fermented milk, cheese, yogurt, juice, probiotics, health supplements, etc. including the composition, and may be used in the form of various other food additives.

In addition, the food composition may further include other ingredients that can give a synergistic effect to the main effect within a range in which the active ingredient does not impair the intended main effect. For example, additives such as fragrances, pigments, disinfectants, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers, and synthetic polymer substances may be further included in order to improve physical properties. In addition, auxiliary components such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, and seaweed extract may be further included. The above ingredients may be appropriately selected and blended by a person skilled in the art according to the formulation or purpose of use, and the amount added may be selected within a range that does not impair the purpose and effect of the present specification. For example, the amount of the components added may range from 0.01 to 5% by weight, or from 0.01 to 3% by weight, based on the total weight of the composition.

Hereinafter, the present invention will be described in more detail through examples. These examples are for illustrative purposes only, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not construed as being limited by these examples.

Example 1. Ant odor ( Aster L.) Preparation of plant extracts and fractions

In this example, bee ants (Aster koraiensis NaKai) as a plant of the genus Aster L. were collected and used in mid-April (young) and mid-August (adult) in Pyeongchang, Gangwon-do. After the dried bee ant odor was minced, 2 L of ethanol was added to 180 g of bee ant odor, followed by heating under reflux extraction for 3 hours, and the extract was filtered. After filtering the extract, 2 L of ethanol was added to the remaining residue, and the method of heating under reflux extraction for 3 hours was repeated two more times to obtain a total of 6 L of the extract. 6 L of the extract was concentrated under reduced pressure at 35° C. to obtain 8.5 g of an ethanol extract.

In addition, the ethanol extract of beehive odor was sequentially fractionated into n-hexane, ethyl acetate, n-butanol and water using a separatory funnel, and as a result, n-hexane fraction (0.94 g), ethyl acetate fraction (1.74 g), n- A butanol fraction (1.86 g) and a water fraction (2.2 g) were obtained.

The prepared extracts and fractions were dissolved in dimethyl sulfoxide (DMSO) and used in the following experiments.

Example 2. Isolation and identification of compounds

The following six fractions were obtained by using reduced pressure column chromatography filled with 5.8 g of the ethanol extract of beehive odor obtained in Example 1 with 85 g of C-18 reverse phase resin. Elution conditions were hexane, ethyl acetate and methanol, starting with 400 mL of hexane/ethyl acetate (10:1 (v/v)), 400 mL of hexane/ethyl acetate (5:1 (v/v)), hexane 400 mL of /ethyl acetate (2:1 (v/v)), 400 mL of hexane/ethyl acetate (1:1 (v/v)), 400 mL of ethyl acetate, and 400 mL of methanol were used as effluent solvents. Of the obtained fractions, the hexane/ethyl acetate (5:1) fraction and the hexane/ethyl acetate (2:1) fraction were combined to prepare a mixed fraction of 400 mg, and 200 mg of the mixed fraction was 65% acetonitrile/water. As a result of separating the main component by high-speed liquid chromatography using as the effluent solvent (column 21 mm × 250 mm; flow rate 10 mL/min), Jimnaster Koreain B (9 mg) represented by Chemical Formula 2, the chemical formula Jimnaster Koreain C (2 mg) represented by 3, Jimnaster Koreain E (0.5 mg) represented by Chemical Formula 4, and 1,8,15-heptadecatriene-11,13 represented by Formula 5 -Diin-10-ol (1 mg) was obtained.

For structural analysis of the compounds, NMR analysis and mass spectrometry were performed as follows. Molecular weight and molecular formula were determined through MS measurement using an Agilent 1100 high-speed fluid chromatography-mass spectrometer (HPLC-ESI-MS), and ¹ H, ¹³ C-NMR spectrum using a nuclear magnetic resonance (Varian 500㎒ NMR). ) Through the analysis, the structure was identified as shown in the following Chemical Formulas 2 to 5. The analysis results are as follows.

[Formula 2]

Jim Naster Korean B:

Pale yellow liquid compound;

Molecular formula C ₁₇ H ₂₂ O ₂ ; UV λmax 200, 237, 251, 266 nm; ESI-MS m/z 281 [M+Na] ⁺ ;

¹ H NMR (500 MHz, CDCl ₃ ) δ 5.81 (1H, ddt, J = 17.0, 10.5, 7.0 Hz, H-2), 5.62 (1H, dtd, J = 10.0, 7.5, 1.0 Hz, H-8) , 5.51 (1H, ddt, J = 10.0, 8.5, 1.5 Hz, H-9), 5.19 (1H, br d, J = 8.5 Hz, H-10), 5.01 (1H, ddt, J = 17.0, 2.0, 2.0 Hz, H-1 _trans ), 4.95 (1H, ddt, J = 10.5, 2.0, 1.0 Hz, H-1 _cis ), 3.19 (1H, qd, J = 5.0, 2.0 Hz, H-16), 3.13 ( 1H, d, J = 2.0 Hz, H-15), 2.12 (2H, dtd, J = 7.0, 7.0, 1.0 Hz, H ₂ -7), 2.05 (2H, dt br t J =7.0, 7.0, 1.0 Hz , H ₂ -3), 1.85 (1H, broad singlet, 10-OH), 1.37-1.42 (4H, m, H ₂ -4, H ₂ -6), 1.31-1.35 (2H, m, H ₂ -5 ), 1.35 (3H, d, J = 5.0 Hz, H-17).

[Formula 3]

Jim Naster Korean C:

Pale yellow liquid compound;

Molecular formula C ₁₉ H ₂₄ O ₃ ; UV λmax 200, 235, 248, 260 nm; ESI-MS m/z 323 [M+Na] ⁺ ;

¹ H NMR (500 MHz, CDCl ₃ ) δ 5.93 (1H, d, J = 6.0 Hz, H-15), 5.88 (1H, dddd, J = 17.0, 10.0, 6.0, 1.0 Hz, H-16), 5.82 (1H, ddtd, J = 17.0, 10.0, 7.0, 1.0 Hz, H-2), 5.62 (1H, dt br t, J = 10.5, 7.5, 1.0 Hz, H-8), 5.55 (1H, d, J = 17.0 Hz, H ₂ -17 _trans ), 5.23 (1H, dd br t, J = 10.5, 8.5, 1.0 Hz, H-9), 5.36 (1H, d, J = 10.0, H ₂ -17 _cis ), 5.21 (1H, d br d, J = 8.5, 1.0 Hz, H-10), 5.01 (1H, d br dt, J = 17.0, 1.5, 1.0 Hz, H ₂ -1 _trans ), 4.95 (1H, ddt, J = 10.0, 1.0, 1.0 Hz, H ₂ -1 _cis ), 2.12 (2H, dtd, J = 8.5, 7.5, 1.0 Hz, H ₂ -7), 2.11 (3H, s, CH ₃ CO), 2.06 ( 2H, dtd, J = 7.0, 7.0, 1.0 Hz, H ₂ -3), 1.37-1.44 (4H, m, H ₂ -4, H ₂ -6), 1.31-1.35 (2H, m, H ₂ -5 ).

[Formula 4]

Jim Naster Korean E:

Pale yellow liquid compound;

Molecular formula C ₁₇ H ₂₄ O ₃ ; UV λmax 200, 237, 251, 265 nm; ESI-MS m/z 299 [M+Na] ⁺ ;

¹ H NMR (500 MHz, CDCl ₃ ) δ 5.82 (1H, ddt, J = 17.0, 10.5, 7.0 Hz, H-2), 5.63 (1H, dt br d, J = 10.0, 7.0, 1.0 Hz, H- 8), 5.53 (1H, ddt, J = 10.0, 8.0, 1.5 Hz, H-9), 5.22 (1H, d br t, J = 8.0, 1.0 Hz, H-10), 5.01 (1H, ddt, J = 17.0, 2.0, 2.0 Hz, H ₂ -1 _trans ), 4.95 (1H, ddt, J = 10.5, 2.0, 1.5 Hz, H ₂ -1 _cis ), 4.62 (1H, dd, J = 4.0, 0.5 Hz, H-15), 4.05 (1H, qdd, J = 6.5, 4.0, 1.5 Hz, H-16), 2.14 (2H, dt, J = 7.0, 6.5 Hz, H ₂ -7), 2.05 (2H, dt, J =7.0, 7.0 Hz, H ₂ -3), 1.32-1.44 (6H, m, H ₂ -4, H ₂ -5, H ₂ -6), 1.35 (3H, d, J = 6.5 Hz, H ₃ -17).

[Formula 5]

1,8,15-heptadecatrien-11,13-diin-10-ol:

Pale yellow liquid compound;

Molecular formula C ₁₇ H ₂₂ O; UV λmax 217, 240, 255, 269, 284 nm; ESI-MS m/z 265 [M+Na] ⁺ ;

¹ H NMR (500 MHz, CDCl ₃ ) δ 6.34 (1H, dq, J = 15.5, 6.5 Hz, H-16), 5.82 (1H, ddt, J = 17.0, 10.0, 8.0 Hz, H-2), 5.61 (1H, dt, J = 10.5, 7.5 Hz, H-8), 5.54 (1H, br d, J = 15.5 Hz, H-15), 5.54 (1H, dd br t, J = 10.5, 8.5, 1.5 Hz , H-9), 5.24 (1H, d, J = 8.5 Hz, H-10), 5.01 (1H, ddt, J = 17.0, 1.5, 1.5 Hz, H ₂ -1 _trans ), 4.95 (1H, ddt, J = 10.0, 2.0, 1.5 Hz, H ₂ -1 _cis ), 2.13 (2H, dtd, J = 7.5, 7.0, 1.0 Hz, H ₂ -7), 2.06 (2H, dt, J = 7.0, 7.0 Hz, H ₂ -3), 1.83 (3H, dd, J = 6.5, 2.0 Hz, H ₃ -17), 1.34-1.43 (4H, m, H ₂ -4, H ₂ -6), 1.23-1.33 (2H, m, H ₂ -5).

Experimental Example 1. Inhibition of the secretion of collagen-degrading enzyme-1

The effect of inhibiting secretion of collagen degrading enzyme-1 (Matrix Metalloproteinase-1, MMP-1) was measured for each of the extracts of bee gill taste and Jimnaster Koreain B obtained through the <Examples> 1 to <Example 2>. Epigallocatechin gallate (EGCG, Sigma, USA) 10 μM concentration was used as a positive control.

^{First, 1×10 5} cells/well of human fibroblasts in a 24-well microtiter plate containing DMEM (Dulbecco's Modified Eagle's Media) medium containing 2.5% fetal bovine serum. Put so as to be, and cultured until about 90% growth. Thereafter, 5, 10, 20 μg/ml of the ethanol extract obtained through <Example 1> to <Example 2> dissolved in a serum-free DMEM medium, and 5, 10, 20 μM of Jimnaster Koreain B , And EGCG was treated at a concentration of 10 μM for 1 hour, washed with DPBS, and then irradiated with 15 mJ using a UV irradiator. Thereafter, 5, 10, 20 μg/ml of the ethanol extracts of bee ant odor of <Example 1> to <Example 2> dissolved in a serum-free DMEM medium, 5, 10, 20 μM of Jimnaster Koreain B, and EGCG was further treated at a concentration of 10 μM. After 24 hours, the cell culture solution was collected, centrifuged, and only the supernatant was obtained.

Thereafter, the degree of collagenase-1 production was measured using a collagenase-1 assay kit (QIA55, Merch & Co., USA) from the collected supernatant. First, the collected cell culture solution was added to a 96-well plate uniformly coated with a primary collagenase antibody, and an antigen-antibody reaction was performed at room temperature for 2 hours. After 2 hours, the primary collagen antibody to which the chromophore was bound was placed in a 96-well plate and reacted for 1 hour. After 1 hour, a color-producing substance was added to induce color development at room temperature for 30 minutes, and then the reaction (color development) was stopped by adding a terminating buffer.As a result, the color of the reaction solution is yellow and the degree of yellow is different depending on the progress of the reaction. appear. The absorbance of a yellow 96-well plate was measured at 450/540 nm using an absorbance meter.

As a result, as shown in FIG. 1, it was confirmed that each of the extract of bee ants and jimnaster Koreain B significantly suppressed the secretion of collagen-degrading enzyme-1 in a concentration-dependent manner.

Experimental Example 2. Increasing the amount of secretion of type-1 procollagen

The effect of increasing the secretion amount of type-1 procollagen was measured for each of the bee ant odor extract and Jim Naster Koreain B obtained through the <Example 1> to <Example 2>. EGCG 10 μM concentration was used as a positive control.

^{First, 1×10 5} cells/well of human fibroblasts in a 24-well microtiter plate containing DMEM (Dulbecco's Modified Eagle's Media) medium containing 2.5% fetal bovine serum. Put so as to be, and incubated until about 90% growth. Thereafter, 5, 10, 20 μg/ml of the ethanol extract obtained through <Example 1> to <Example 2> dissolved in a serum-free DMEM medium, and 5, 10, 20 μM of Jimnaster Koreain B , And EGCG was treated at a concentration of 10 μM for 1 hour, washed with DPBS, and then irradiated with 15 mJ using a UV irradiator. Thereafter, 5, 10, 20 μg/ml of the ethanol extracts of bee ant odor of <Example 1> to <Example 2> dissolved in a serum-free DMEM medium, 5, 10, 20 μM of Jimnaster Koreain B, and EGCG was further treated at a concentration of 10 μM. After 24 hours, the cell culture solution was collected, centrifuged, and only the supernatant was harvested. A peptide (procollagen type-I C-peptide, PIP), an indicator of collagen synthesis, was prepared using an ELISA kit (MK101, Takara Bio Ink, Japan) Was used to quantitatively measure the effect on collagen production.

First, an antibody-PIP conjugate labeled with peroxidase was added to a 96-well plate uniformly coated with a mouse monoclonal antibody against procollagen and reacted. Then, the collected cell culture solution was added and reacted in an incubator at 37° C. for 3 hours, followed by color development by adding a substrate solution. After allowing to stand at room temperature for 15 minutes, a reaction stopping solution was added to stop the reaction, and absorbance was measured at 450 nm using an absorbance meter.

As a result, as shown in FIG. 2, it was found that each of the bee ant odor extract and Jim Naster Koreain B had excellent effects in promoting the production and secretion of type-1 procollagen.

Experimental Example 3. Inhibition of the expression level of collagen degrading enzyme (MMP)

The effect of inhibiting the expression level of collagen-degrading enzyme (Matrix Metalloproteinase, MMP) was measured for each of the extracts of bee gill odor and Jimnaster Koreain B obtained through the <Example 1> to <Example 2>. EGCG 10 μM concentration was used as a positive control.

^{First, 2×10 6} cells/well of human keratinocytes in a 6-well microtiter plate containing DMEM (Dulbecco's Modified Eagle's Media) medium containing 2.5% fetal bovine serum. ), and incubated until about 90% growth. Thereafter, 5, 10, 20 μg/ml of the ethanol extract obtained through <Example 1> to <Example 2> dissolved in a serum-free DMEM medium, and 5, 10, 20 μM of Jimnaster Koreain B , And EGCG was treated at a concentration of 10 μM for 1 hour, washed with DPBS, and then irradiated with 15 mJ using a UV irradiator. Thereafter, 5, 10, 20 μg/ml of the ethanol extracts of bee ant odor of <Example 1> to <Example 2> dissolved in a serum-free DMEM medium, 5, 10, 20 μM of Jimnaster Koreain B, and EGCG was further treated at a concentration of 10 μM. After 24 hours, total RNA was harvested from the cells using a TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed, and then RT-PCR analysis was performed as follows. First, for cDNA synthesis, the RNA was reverse transcribed with reverse transcriptase. RT-PCR was performed with the following specific primers:

β-actin

Forward primer: 5'-AGCCATGTACGTAGCCATCC-3' (SEQ ID NO: 1)

Reverse primer: 5'-CTCTCAGCTGTGGTGGTGAA-3' (SEQ ID NO: 2)

MMP-1

Forward primer: 5'-ACAGCTTCCCAGCGACTCTA-3' (SEQ ID NO: 3)

Reverse primer: 5'-CTCTTGGCAAATCTGGCGTG-3' (SEQ ID NO: 4)

MMP-2

Forward primer: 5'-CGCATCTGGGGCTTTAAACAT-3' (SEQ ID NO: 5)

Reverse primer: 5'-CCATTAGCGCCTCCATCGTA-3' (SEQ ID NO: 6)

MMP-9

Forward primer: 5'-CATCCGGCACCTCTATGGTC-3' (SEQ ID NO: 7)

Reverse primer: 5'-CATCGTCCACCGGACTCAAA-3' (SEQ ID NO: 8)

Each relative mRNA expression level value was normalized to the β-actin value.

As a result, as shown in Fig. 3, it was found that each of the extract of bee ant gill odor and Jim Naster Koreain B significantly inhibited the expression levels of collagen-degrading enzymes (MMP-1, MMP-2, MMP-9).

Experimental Example 4. Increasing the amount of collagen expression

The effect of increasing the expression level of collagen for each of the extract of bee ant odor obtained through the above <Example 1> to <Example 2> and Jim Naster Koreain B was measured. EGCG 10 μM concentration was used as a positive control.

^{First, 2×10 6} cells/well of human keratinocytes in a 6-well microtiter plate containing DMEM (Dulbecco's Modified Eagle's Media) medium containing 2.5% fetal bovine serum. ), and incubated until about 90% growth. Thereafter, 5, 10, 20 μg/ml of the ethanol extract obtained through <Example 1> to <Example 2> dissolved in a serum-free DMEM medium, and 5, 10, 20 μM of Jimnaster Koreain B , And EGCG was treated at a concentration of 10 μM for 1 hour, washed with DPBS, and then irradiated with 15 mJ using a UV irradiator. Thereafter, 5, 10, 20 μg/ml of the ethanol extracts of bee ant odor of <Example 1> to <Example 2> dissolved in a serum-free DMEM medium, 5, 10, 20 μM of Jimnaster Koreain B, and EGCG was further treated at a concentration of 10 μM. After 24 hours, total RNA was harvested from the cells using a TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed, and then RT-PCR analysis was performed as follows. First, for cDNA synthesis, the RNA was reverse transcribed with reverse transcriptase. RT-PCR was performed with the following specific primers:

β-actin

Forward primer: 5'-AGCCATGTACGTAGCCATCC-3' (SEQ ID NO: 1)

Reverse primer: 5'-CTCTCAGCTGTGGTGGTGAA-3' (SEQ ID NO: 2)

COL1A1

Forward primer: 5'-TGAGCGGACGCTAACCCCCT-3' (SEQ ID NO: 9)

Reverse primer: 5'-CAGACGGGACAGCACTCGCC-3' (SEQ ID NO: 10)

Each relative mRNA expression level value was normalized to the β-actin value.

As a result, as shown in FIG. 4, it was found that each of the extract of bee ant odor and Jim Naster Koreain B had an excellent effect on increasing the expression level of collagen COL1A1.

An example of the formulation of the composition according to an aspect of the present invention is described below, but it can be applied to various other formulations, and this is not intended to limit the present invention, but is intended to be described in detail.

[Formulation Example 1] Nutritional lotion (milk lotion)

Nutrient cosmetic water was prepared according to a conventional method by using the ethanol extract of bee ant odor or Jimnaster Koreain B of the <Example 1> to <Example 2> according to the nutritional cosmetic water formulation ratio of Table 1 below.

Table 1.

[Formulation Example 2] Softening lotion (skin lotion)

Softening lotion was prepared according to a conventional method by using the ethanol extract of beehive taste or jimnaster Koreain B of the <Example 1> to <Example 2> according to the ratio of the softening lotion formulation shown in Table 2 below.

Table 2.

[Formulation Example 3] Nourishing Cream

A nutrient cream was prepared according to a conventional method by using the ethanol extract of bee ant odor or Jimnaster Koreain B of the <Example 1> to <Example 2> according to the nutritional cream formulation ratio shown in Table 3 below.

Table 3.

[Formulation Example 4] Massage Cream

A massage cream was prepared according to a conventional method by using the ethanol extract of bee ant odor or Jim Naster Koreain B of the <Example 1> to <Example 2> according to the ratio of the massage cream formulation shown in Table 4 below.

Table 4.

[Formulation Example 5] Pack

A pack was prepared according to a conventional method by using the ethanol extract of bee ant odor or jimnaster Koreain B of the <Example 1> to <Example 2> according to the ratio of the pack formulation shown in Table 5 below.

Table 5.

[Formulation Example 6] Gel

A gel was prepared according to a conventional method by using the ethanol extract of beehive odor or jimnaster Koreain B of the <Example 1> to <Example 2> according to the gel formulation ratio shown in Table 6 below.

Table 6.

[Formulation Example 7] Health Food

Ethanol extract of beehive odor of <Example 1> to <Example 2> or Jimnaster Koreain B 1000 mg, vitamin A acetate 70 ㎍, vitamin E 1.0 mg, vitamin B1 0.13 mg, vitamin B2 0.15 mg, vitamin B6 0.5 mg, vitamin B12 0.2 μg, vitamin C 10 mg, biotin 10 μg, nicotinic acid amide 1.7 mg, folic acid 50 μg, pantothenic acid calcium 0.5 mg, ferrous sulfate 1.75 mg, zinc oxide 0.82 mg, magnesium carbonate 25.3 mg, monophosphate Potassium 15 mg, dicalcium phosphate 55 mg, potassium citrate 90 mg, calcium carbonate 100 mg, and magnesium chloride 24.8 mg can be mixed and prepared, and the mixing ratio may be arbitrarily modified, and the general health food manufacturing method According to the above ingredients are mixed, and then granules are prepared, and can be used for preparing a health food composition according to a conventional method.

[Formulation Example 8] Health Drink

Purified water was added to the ethanol extract of beehive odor of the <Example 1> to <Example 2> or 1000 mg of Jimnaster Koreain B, 1000 mg of citric acid, 100 g of oligosaccharide, 2 g of plum concentrate, and 1 g of taurine to obtain a total of 900 ml. After mixing the above ingredients according to the normal health drink manufacturing method, the resulting solution is stirred and heated at 85°C for about 1 hour, filtered, obtained in a sterilized 2 L container, sealed and sterilized, and then stored in the refrigerator. It can be used to prepare the composition.

[Formulation Example 9] Chewing gum

20% by weight of gum base, 76.9% by weight of sugar, 1% by weight of flavor, and 2% by weight of water, and 0.1% by weight of the ethanol extract of beehive odor of <Example 1> to <Example 2> or Jim Naster Korea B Chewing gum was prepared by a conventional method.

[Formulation Example 10] Candy

Sugar 60% by weight, starch syrup 39.8% by weight, and 0.1% by weight of flavor, and 0.1% by weight of the ethanol extract or Jimnaster Koreain B of <Example 1> to <Example 2> were mixed to prepare candy by a conventional method. Was prepared.

[Formulation Example 11] Biscuit

Power Level 1 25.59% by weight, Gravity Level 1 22.22% by weight, sugar 4.80% by weight, salt 0.73% by weight, glucose 0.78% by weight, palm shortening 11.78% by weight, ammonium 1.54% by weight, sodium bicarbonate 0.17% by weight, sodium bisulfite 0.16% , Rice flour 1.45% by weight, vitamin B₁0.0001% by weight, vitamin B₂0.0001% by weight, milk flavor 0.04% by weight, water 20.6998% by weight, whole milk powder 1.16% by weight, substitute powdered milk 0.29% by weight, monobasic calcium phosphate 0.03% by weight , 0.29% by weight of spray salt and 7.27% by weight of spray oil, and the ethanol extract of beehive odor of <Example 1> to <Example 2> or B% by weight of Jimnaster Korea were mixed to prepare a biscuit by a conventional method.

[Formulation Example 12] Powder

A powder was prepared by mixing the ethanol extract of beehive odor of the above <Example 1> to <Example 2> or 50 mg of Jimnaster Koreain B, and 2 g of crystalline cellulose, and then filled in an airtight cloth according to a conventional powder preparation method. .

[Formulation Example 13] Tablet

After mixing the ethanol extract of beehive odor of <Examples 1> to <Example 2> or 50 mg of Zimnaster Koreain B, 400 mg of crystalline cellulose, and 5 mg of magnesium stearate, tablets were prepared by tableting according to a conventional tablet manufacturing method. Was prepared.

[Formulation Example 14] Capsule

A conventional capsule preparation method after mixing the ethanol extract of beehive odor of the <Examples 1> to <Example 2> or 30 mg of Jimnaster Koreain B, 100 mg of whey protein, 400 mg of crystalline cellulose, 6 mg of magnesium stearate According to the following, a gelatin capsule was filled to prepare a capsule.

[Formulation Example 15] Injection

According to a conventional injection preparation method, the active ingredient is dissolved in distilled water for injection and the pH is adjusted to about 7.5, and then the ethanol extract of beehive odor of <Examples 1> to <Example 2> or Jimnaster Koreain B 100 mg, Distilled water for injection and a pH adjuster were mixed, filled in a 2 ml ampoule, and sterilized to prepare an injection.

As described above, specific parts of the present invention have been described in detail, and for those of ordinary skill in the art, these specific techniques are only preferred embodiments, and the scope of the present invention is not limited thereto. It will be obvious. Therefore, it will be said that the practical scope of the present invention is defined by the appended claims and their equivalents.

<110> KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY <120> ANTI-AGING COMPOSITION COMPRISING ASTER PLANT EXTRACTS <130> 17P612/IND <160> 10 <170> KopatentIn 2.0 <210> 1 <211> 20 <212> DNA <213> beta-actin forward primer <400> 1 agccatgtac gtagccatcc 20 <210> 2 <211> 20 <212> DNA <213> beta-actin reverse primer <400> 2 ctctcagctg tggtggtgaa 20 <210> 3 <211> 20 <212> DNA <213> MMP-1 forward primer <400> 3 acagcttccc agcgactcta 20 <210> 4 <211> 20 <212> DNA <213> MMP-1 reverse primer <400> 4 ctcttggcaa atctggcgtg 20 <210> 5 <211> 21 <212> DNA <213> MMP-2 forward primer <400> 5 cgcatctggg gctttaaaca t 21 <210> 6 <211> 20 <212> DNA <213> MMP-2 reverse primer <400> 6 ccattagcgc ctccatcgta 20 <210> 7 <211> 20 <212> DNA <213> MMP-9 forward primer <400> 7 catccggcac ctctatggtc 20 <210> 8 <211> 20 <212> DNA <213> MMP-9 reverse primer <400> 8 catcgtccac cggactcaaa 20 <210> 9 <211> 20 <212> DNA <213> COL1A1 forward primer <400> 9 tgagcggacg ctaaccccct 20 <210> 10 <211> 20 <212> DNA <213> COL1A1 reverse primer <400> 10 cagacgggac agcactcgcc 20

Claims (8)

A cosmetic composition for improving skin wrinkles or skin elasticity comprising a compound represented by the following formula (2), a derivative thereof, a salt thereof, a hydrate thereof, a solvate thereof, a prodrug thereof or an isomer thereof as an active ingredient.
(2)

delete The method according to claim 1,
Wherein the compound is isolated from an extract of Aster L. plant or a fraction thereof.
The method according to claim 1,
Wherein the compound is contained in an amount of 0.0001 to 10% by weight based on the total weight of the composition.
A food composition for improving skin wrinkles or skin elasticity comprising a compound represented by the following formula (2), a derivative thereof, a salt thereof, a hydrate thereof, a solvate thereof, a prodrug thereof or an isomer thereof as an active ingredient.
(2)

delete 6. The method of claim 5,
Wherein the compound is isolated from an extract of Aster L. plant or a fraction thereof, to improve skin wrinkles or skin elasticity.
6. The method of claim 5,
Wherein the compound is contained in an amount of 0.0001 to 10% by weight based on the total weight of the composition.

Images